Columbia has taken an equity stake in the antiviral therapeutics producer, co-founded by two of its faculty members.

RenBio, a US-based antiviral therapy developer, has raised $24m in a series A round and secured a licence for its lead candidate developed at Columbia University.
Industrial conglomerate Ruentex Group led the series A round, while Columbia University secured an equity stake as part of the licence.
RenBio is working on antibody therapeutics. Its Columbia-licensed asset RB-100 is a bispecific antibody compound targeting Sars-Cov-2, the virus that causes covid-19.
The compound was created in the lab of…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Edison Fu

Edison Fu is a reporter and Asia liaison at Global Corporate Venturing.
email
Linked in